Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months

Author Wu, Lihteh Google Scholar
Arevalo, Jose Fernando Google Scholar
Berrocal, Maria Hortensia Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Roca, Jose Antonio Google Scholar
Morales-Canton, Virgilio Google Scholar
Alezzandrini, Arturo A. Google Scholar
Diaz-Llopis, Manuel Jose Google Scholar
Institution Inst Cirugia Ocular
Ctr Caracas
Univ Puerto Rico
Universidade Federal de São Paulo (UNIFESP)
Clin Ricardo Palma
Hosp Luis Sanchez Bulnes
Univ Buenos Aires
Inst Oftalmol Valencia
Abstract Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion.Methods: An interventional, retrospective, comparative multicenter study was conducted of 63 eyes with macular edema secondary to branch retinal vein occlusion that were treated primarily with intravitreal bevacizumab (38 eyes, 1.25 mg; 25 eyes, 2.5 mg). The main outcome measures were the CMT and the change of BCVA at 24 months.Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye was 3.6 in the 1.25-mg group and 4.3 in the 2.5-mg group (P = 0.4770). At 24 months, in the 1.25-mg group, the logarithm of the minimum angle of resolution BCVA improved from baseline 0.38 +/- 0.63 (P < 0.0001) units to 0.64 +/- 0.6 units for the 2.5-mg group (P < 0.0001). In the 1.25-mg group, 26 (68%) eyes gained >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity and 2 (5%) eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg group, 18 (72%) eyes improved >= 3 of Early Treatment of Diabetic Retinopathy Study visual acuity, and none of the eyes lost >= 3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg group improved from 453 +/- 140 mu m to 244 +/- 125 mu m (P < 0.0001) versus 444 +/- 175 mu m to 234 +/- 80 mu m in the 2.5-mg group (P < 0.0001). There were no cases of endophthalmitis. No systemic adverse events were reported.Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving BCVA and reducing CMT in macular edema secondary to branch retinal vein occlusion. No statistically significant differences were found between the two dose groups with regard to the number of injections, CMT, and change in BCVA. RETINA 29:1396-1403, 2009
Keywords bevacizumab
branch retinal vein occlusion
intravitreal injections
macular edema
retinal vein occlusions
VEGF
Language English
Date 2009-11-01
Published in Retina-the Journal Of Retinal And Vitreous Diseases. Philadelphia: Lippincott Williams & Wilkins, v. 29, n. 10, p. 1396-1403, 2009.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 1396-1403
Origin http://dx.doi.org/10.1097/IAE.0b013e3181bcef53
Access rights Closed access
Type Article
Web of Science ID WOS:000271787600002
URI http://repositorio.unifesp.br/11600/45216

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account